Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLINCH-3: ATG-022 vs Investigator's Choice in CLDN18.2-Positive Advanced Gastric/GEJ Adenocarcinoma
NCT07795346Phase 3Recruiting
- Sponsor
- Antengene
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 3 trial of ATG-022 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Antengene. Started Sep 2026; status: recruiting.
02
Drugs
ATG-022
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07795346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795346.